LEARNING OBJECTIVES
Upon conclusion of this activity, participants should be able to:

1. Describe how whole genome sequencing (WGS) can be implemented in a clinical setting and used to improve the diagnostics of myeloid neoplasms.
2. Identify how genomic data is used to diagnose myeloid neoplasms and manage patient risk.
3. Recognize how sequencing based-minimal residual disease testing can be used to monitor AML and MDS patients for disease recurrence and treatment response. 

ATTENDANCE / CREDIT
Text the session code (provided only at the session) to 507-200-3010 within 48 hours of the live presentation to record attendance. All learners are encouraged to text attendance regardless of credit needs. This number is only used for receiving text messages related to tracking attendance. Additional tasks to obtain credit may be required based on the specific activity requirements and will be announced accordingly. Swiping your badge will not provide credit; that process is only applicable to meet GME requirements for Residents & Fellows.

TRANSCRIPT
Any credit or attendance awarded from this session will appear on your Transcript.

For disclosure information regarding Mayo Clinic School of Continuous Professional Development accreditation review committee member(s) and staff, please go here to review disclosures.